Infections caused by Candida species manifest in a number of diseases, including candidemia, vulvovaginal candidiasis,
endocarditis, and peritonitis. Candida species have been reported to possess lipolytic activity due to the secretion of lipolytic
enzymes such as esterases, lipases and phospholipases. Extra-cellular hydrolytic enzymes seem to play an important role in
Candida overgrowth. Candidiasis is commonly treated with antimycotics such as clotrimazole and nystatin. The
antimycotics bind to a major component of the fungal cell membrane (ergosterol), forming pores that lead to death of the
fungus. However, the secondary effects caused during such treatment have aroused a need to develop a treatment based on
lipase inhibition. Nonetheless, no such lipase inhibitors for candidiasis treatment are currently available. Thus, we have
performed a docking study with the natural inhibitor, orlistat or tetrahydrolipstatin. Our results have shown ten possible
binding inhibitors to Candida rugosa lipase (CRL), out of which one possibility was selected, based on the weakest interatomic
distance of 2.7 Å. Therefore, we propose the selection and design of a potential inhibitor candidate, orlistat for the
treatment of candidiasis infections. However, this study has to be supported with in vitro and in vivo experiments to
demonstrate the effectiveness of orlistat in lipase inhibition.